The case for & against
Bull & Bear analysis
Bearish
China Biologic Products Holdings (CBPO) was once a dominant player in China's biopharmaceutical industry, focusing on the development, manufacture, and sale of human plasma-based products and immunoglobulin therapies. They operated primarily in the healthcare sector, with a strong emphasis on addressing the needs of patients with immunodeficiencies and other serious diseases. However, the company underwent substantial corporate changes, including a merger and subsequent privatization, leading to its delisting from NASDAQ in April 2021 and ceasing its public trading operations.
Bull says
- ↑Leading share of China’s plasma-derived products market pre-delisting
- ↑Diversified immunoglobulin and plasma therapy portfolio
- ↑Strong R&D pipeline for next-gen plasma-based treatments
- ↑China’s plasma therapy demand grew high-single digits historically
- ↑Extensive hospital distribution network nationwide
- ↑Potential relisting could catalyze valuation uplift
Bear says
- ↓Delisted from NASDAQ in April 2021, eliminating public liquidity
- ↓Privatization removed all financial transparency and halted disclosures
- ↓No public KPIs or earnings reported post-privatization
- ↓Opaque operations hinder assessment of financial health or growth
- ↓Competition and tech disruption may erode private-market moat
- ↓No clear timeline or plan for relisting or strategic direction